The Excitement Surrounding Immunotherapies for Melanoma
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the excitement surrounding immunotherapies for the treatment of patients with melanoma.
Clinical Pearls
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the excitement surrounding immunotherapies for the treatment of patients with melanoma.
- By taking away the PD-1/PD-L1 break, which is relevant inside the tumor, it is possible to study a tumor and determine if the PD-1/PD-L1 regulatory pathway was turning off T cells
- PD-1/PD-L1 inhibitors are easier to study than older immunotherapies that require turning on the immune system
- Researchers are able to determine who will respond to PD-1/PD-L1 inhibitors and how to intervene in those patients that will not
Response Time and BRAF Status Factor Into IO Selection for Melanoma
January 29th 2025During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.
Read More
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
